ANCA-Negative, Pauci-Immune Crescentic Glomerulonephritis After GLP-1 Receptor Agonist Exposure (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0759; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Notably, she had initiated dulaglutide for weight loss 4 weeks prior to presentation, which she discontinued after developing a localized skin reaction...Given severe kidney involvement, she was treated with cyclophosphamide and glucocorticoids resulting in resolution of hematuria and improvement in kidney function to a sCr of 130 μmol/L at 8 weeks. She received maintenance rituximab for 2 years and remained in renal remission with stable kidney function and inactive urine sediment...This case highlights the diagnostic challenge of ANCA-negative glomerulonephritis in the absence of a serologic biomarker. Timely kidney biopsy is crucial in patients with unexplained kidney injury following recent drug exposure to enable early treatment and prevent irreversible damage."
Acute Kidney Injury • Cardiovascular • Diabetes • Endocrine Disorders • Genetic Disorders • Glomerulonephritis • Lupus Nephritis • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • Vasculitis
|
|
Sara Almutar; Loulwa Alsharhan; Ahmed Altaleb
|